Trial record 1 of 1 for: NCT01866826
Previous Study | Return to List | Next Study
Rifaximin for Chronic Immune Activation in People With HIV
|ClinicalTrials.gov Identifier: NCT01866826|
Recruitment Status : Active, not recruiting
First Posted : June 3, 2013
Last Update Posted : January 25, 2017
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
University of Pittsburgh
Walter Reed Navy MMC
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Active, not recruiting|
|Actual Primary Completion Date :||June 30, 2016|
|Estimated Study Completion Date :||May 18, 2018|
Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009 Sep-Oct;17(4):118-23.
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008 Oct 21;5(10):e203. doi: 10.1371/journal.pmed.0050203.
Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003 May 15;187(10):1534-43. Epub 2003 Apr 23.